Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Incidence of Micro- and Macrovascular Complications among Persons with Type 2 Diabetes with and without Severe Mental Illness. A Nationwide Study

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  4. The trans-ancestral genomic architecture of glycemic traits

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: To investigate the impact of a multifactorial treatment programme in a real-life setting on clinical outcomes and estimated cardiovascular disease (CVD) risk.

DESIGN: A retrospective observational cohort study, using data from the electronic medical records and national registers.

SETTING: Tertiary diabetes centre in Denmark.

PARTICIPANTS: Patients with type 2 diabetes (n=4299) referred to a programme with focus on treatment of hyperglycaemia, hypertension and dyslipidaemia between 1 January 2001 and 1 April 2016.

OUTCOMES: Primary outcomes were changes in haemoglobin A1c (HbA1c), blood pressure (BP) and low-density lipoprotein (LDL) cholesterol as well as proportion reaching treatment targets. Our secondary outcome was to investigate changes in antidiabetic, antihypertensive and lipid-lowering treatment, together with the impact on estimated CVD risk. Linear mixed model for repeated measurements were used for continuous variables and logistic regression for dichotomous variables.

RESULTS: The patients achieved a mean±SD decrease in HbA1c, systolic and diastolic BP and LDL cholesterol of 1.0%±0.04% (10.6±0.4 mmol/mol), 6.3±0.4 mm Hg, 2.7±0.2 mm Hg and 0.32±0.02 mmol/L, respectively (p<0.0001). The proportion of patients who met the treatment goal for HbA1c(<7% (<53 mmol/mol)) increased from 31% to 58% (p<0.0001); for BP (<130/80 mm Hg) from 24% to 34% (p<0.0001), and for LDL cholesterol (<2.5 mmol/L (patients without previous CVD) or <1.8 mmol/L (patients with previous CVD)) from 52% to 65%. Those reaching all three guideline treatment targets increased from 4% to 15% (p<0.0001), and when relaxing the BP target to <140/85 from 8% to 24%. The estimated CVD risk was relatively reduced by 15.2% using the Swedish National Diabetes Register risk engine and 30.9% using the UK Prospective Diabetes Study risk engine.

CONCLUSIONS: Our data support that short-term multifactorial treatment of patients with glycaemic dysregulation in a specialist outpatient setting is both achievable and effective, and associated with a clinically meaningful improvement in CVD risk.

Original languageEnglish
JournalBMJ Open
Volume8
Issue number3
Pages (from-to)e019214
ISSN2044-6055
DOIs
Publication statusPublished - 17 Mar 2018

    Research areas

  • Journal Article, Research Support, Non-U.S. Gov't

ID: 53599896